| Patents for A61P 19 - Drugs for skeletal disorders (81,981) |
|---|
| 02/12/2003 | CN1395957A Plaster for setting up bone, dispersing stasis and analgesia and its preparing process |
| 02/12/2003 | CN1101221C Traditioal Chinese medicine of clenaing away heat and toxic material, dredging the channel, invigorating yin and yang |
| 02/12/2003 | CN1101219C Chinese-medicinal pills for treating ischemic necrosis of femur head and its preparation process |
| 02/12/2003 | CN1101202C Compound Chinese medicine preparation for treating hyperostegogeny |
| 02/12/2003 | CN1101201C Chinese medicine for making lumber stronger and consolidating vital energy of kidney |
| 02/11/2003 | US6518421 Process for the preparation of epothilone analogs |
| 02/11/2003 | US6518397 Pharmaceuticals for modulating hormone responsiveness |
| 02/11/2003 | US6518319 Method of preparing and using compositions extracted from vegetable matter for the treatment of female symptoms |
| 02/11/2003 | US6518316 Cytokine production and tyrosine kinase inhibitors |
| 02/11/2003 | US6518301 Better selectivity than estrogen for the estrogen receptor-beta over receptor-alpha; treatment of Alzheimer's disease, anxiety, depression, osteoporosis, cardiovascular disease, rheumatoid arthritis, or prostate cancer |
| 02/11/2003 | US6518292 Heterocyclic aromatic compounds usefuls as growth hormone secretagogues |
| 02/11/2003 | US6518286 Compounds |
| 02/11/2003 | US6518285 Piperidinyloxy and pyrrolidinyloxy oxazolidinone antibacterials |
| 02/11/2003 | US6518277 Disrupting leukocyte function |
| 02/11/2003 | US6518267 Protease inhibitors |
| 02/11/2003 | US6518239 Dry powder compositions having improved dispersivity |
| 02/11/2003 | US6518063 Osf2/Cbfa1 nucleic acids and methods of use therefor |
| 02/11/2003 | US6518046 DNA (RNA) encoding such chemolcine polypeptides. Moreover, a procedure for producing such polypeptides by recombinant techniques is disclosed. Also disclosed are methods for utilizing such Ck beta -9 polypeptides for the treatment of |
| 02/10/2003 | WO2002014320A2 Novel substituted diaryl azepine derivatives as integrin ligands |
| 02/10/2003 | CA2419078A1 Substituted diaryl azepine derivatives as integrin ligands |
| 02/06/2003 | WO2003010299A1 Probiotic lactobacillus casei strains |
| 02/06/2003 | WO2003010298A1 'probiotic lactobacillus salivarius strains |
| 02/06/2003 | WO2003010297A1 Probiotic bifidobacterium strains |
| 02/06/2003 | WO2003010286A2 Nucleic acids, polypeptides, and methods for modulating apoptosis |
| 02/06/2003 | WO2003010282A2 Interleukin-1 beta antibodies |
| 02/06/2003 | WO2003010202A1 Concatameric immunoadhesion |
| 02/06/2003 | WO2003010164A1 Arylsulfonamide derivatives as c-jun-n-terminal kinases (jnk's) inhibitors |
| 02/06/2003 | WO2003010135A1 Novel phenylpropionic acid derivatives |
| 02/06/2003 | WO2003009872A1 Remedies for diseases with bone mass loss having ep4 agonist as the active ingredient |
| 02/06/2003 | WO2003009867A1 Use of biologically active hiv-1 tat, fragments or derivates thereof, to target and/or to activate antigen-presenting cells, and/or to deliver cargo molecules for preventive or therapeutic vaccination and/or to treat other diseases |
| 02/06/2003 | WO2003009860A1 Preparation used for the topical treatment of pains and skin diseases |
| 02/06/2003 | WO2003009855A2 Organo-phosphorous compounds for activating gamma/delta t cells |
| 02/06/2003 | WO2003009847A1 Substituted piperidines as modulators of the melanocortin receptor |
| 02/06/2003 | WO2003009841A1 Novel pyrroles having hypolipidemic hypocholesteremic activities, process for their preparation and pharmaceutical compositions containing them and their use in medicine |
| 02/06/2003 | WO2003009813A2 Methods of treating neuropilin-mediated diseases |
| 02/06/2003 | WO2003009807A2 Cytoprotective compounds, pharmaceutical and cosmetic formulations, and methods |
| 02/06/2003 | WO2003009804A2 Conformationally constrained parathyroid hormone (pth) analogs |
| 02/06/2003 | WO2003009741A2 Methods for treating joint inflammation, pain, and loss of mobility |
| 02/06/2003 | WO2002095034A3 A retinoic acid metabolizing cytochrome p450 |
| 02/06/2003 | WO2002079146A3 Compounds useful as modulators of melanocortin receptors and pharmaceutical compositions comprising same |
| 02/06/2003 | WO2002067851A3 Method for treating fibrotic diseases or other indications iiic |
| 02/06/2003 | WO2002064586A3 Heterocyclic inhibitors of erk2 and uses thereof |
| 02/06/2003 | WO2002061110A3 Nucleic acid derivatives |
| 02/06/2003 | WO2002059112A3 Pyrazole compounds useful as protein kinase inhibitors |
| 02/06/2003 | WO2002041843A3 Antiinflammation agents |
| 02/06/2003 | WO2002028904A3 Human anti-cd40 antibodies |
| 02/06/2003 | WO2002020722A3 Methods and compositions for in vitro targeting |
| 02/06/2003 | WO2002019963A3 Synthetic erythropoiesis stimulating proteins |
| 02/06/2003 | WO2002010217A9 Endothelial cell expression patterns |
| 02/06/2003 | WO2002010137A9 Indazole derivatives as jnk inhibitors |
| 02/06/2003 | WO2002007733A3 Method for enhancing bone mineral density gain by administration of raloxifene |
| 02/06/2003 | WO2002002095A3 Compositions for treating bacterial infections containing oxazolidinone compound, sulbactam and an ampicillin |
| 02/06/2003 | WO2001082973A3 Viral and non-viral vectors as vehicles for delivering transgenes for treating bone pathologies |
| 02/06/2003 | WO2001066139A9 Use of a compound that selectively binds to cd123 to impair hematologic cancer progenitor cell |
| 02/06/2003 | WO2001047946A3 GFRα1-RET SPECIFIC AGONISTS AND METHODS THEREFOR |
| 02/06/2003 | US20030028038 Semi-synthetic taxanes with antitumor and antiangiogenetic activities |
| 02/06/2003 | US20030028028 1-oxo- and 1,3-dioxoisoindolines and method of reducing inflammatory cytokine levels |
| 02/06/2003 | US20030028008 Nucleotide sequences coding polypeptide for use in the treatment of urogenital, tumor, antherosclerotic and kidney disorders |
| 02/06/2003 | US20030027999 143 human secreted proteins |
| 02/06/2003 | US20030027845 Ether derivatives useful as inhibitors of PDE4 isozymes |
| 02/06/2003 | US20030027840 Estrogen receptor modulators |
| 02/06/2003 | US20030027820 Method for treating fibrotic diseases or other indications V |
| 02/06/2003 | US20030027807 Vitronectin receptor antagonists, their preparation and their use |
| 02/06/2003 | US20030027804 Administering to the mammal a menopause disorder effective amount of an orally deliverable pharmaceutically- acceptable sex hormone binding globulin synthesis inhibiting agent, and at least one of a non-orally deliverable steroids |
| 02/06/2003 | US20030027794 N-heterocyclic derivatives as NOS inhibitors |
| 02/06/2003 | US20030027785 Administering to a subject a purinergic receptor agonist in an amount therapeutically effective to alter the amount or formulation of synovial fluids |
| 02/06/2003 | US20030027261 Novel genes TZap7/A, TZap7/B and TZap7 involved in T cell activation and uses thereof |
| 02/06/2003 | US20030027253 Nucleotides equences codin polypeptide for use in the treatment of cancer |
| 02/06/2003 | US20030027211 Fetuin-MGP-mineral complex in serum |
| 02/06/2003 | US20030027158 Novel nucleic acid sequences encoding human breast tumor-associated protein 47-like polypeptides |
| 02/06/2003 | US20030027151 Nucleotide sequences coding polypeptide for use in the diagnosis and treatment of bone disorders |
| 02/06/2003 | US20030026860 Administering calcium compoound and fat blend |
| 02/06/2003 | US20030026805 Genetic engineering; monoclonal antibody grafted to tumor necrosis factor |
| 02/06/2003 | US20030026803 Compositions for inhibiting macrophage activity |
| 02/06/2003 | CA2857312A1 Nucleic acids, polypeptides, and methods for modulating apoptosis using deoxyhypusine synthase (dhs) |
| 02/06/2003 | CA2454822A1 Nucleic acids, polypeptides, and methods for modulating apoptosis using apoptosis-specific eif-5a |
| 02/06/2003 | CA2454805A1 Probiotic lactobacillus casei strains |
| 02/06/2003 | CA2454803A1 Probiotic bifidobacterium strains |
| 02/06/2003 | CA2452328A1 Substituted piperidines as modulators of the melanocortin receptor |
| 02/06/2003 | CA2452259A1 Arylsulfonamide derivatives as c-jun-n-terminal kinases (jnk's) inhibitors |
| 02/06/2003 | CA2452159A1 Cytoprotective compounds, pharmaceutical and cosmetic formulations, and methods |
| 02/05/2003 | WO2002014280A1 Piperidine derivatives and drugs containing these derivatives as the active ingredient |
| 02/05/2003 | EP1281702A2 Calcium receptor active molecules |
| 02/05/2003 | EP1281401A2 The medical effect of Jojoba oil |
| 02/05/2003 | EP1281397A1 Orally administered controlled drug delivery system providing temporal and spatial control |
| 02/05/2003 | EP1280891A1 Methods for identifying compounds useful for inhibiting geranylgeranyl diphosphate synthase |
| 02/05/2003 | EP1280826A2 Methods and compositions of matter concerning april/g70, bcma, blys/agp-3, and taci |
| 02/05/2003 | EP1280820A2 Anti-inflammatory compounds and uses thereof |
| 02/05/2003 | EP1280815A1 29 human secreted proteins |
| 02/05/2003 | EP1280806A1 THIENO 2,3-d]PYRIMIDINEDIONES AND THEIR USE AS PHARMACEUTICALS |
| 02/05/2003 | EP1280799A1 Ortho-substituted anthranilic acid amides and their use as medicaments |
| 02/05/2003 | EP1280777A1 Tetrahydroisoquinoline analogs useful as growth hormone secretagogues |
| 02/05/2003 | EP1280776A1 Substituted benzoic acid amides and use thereof for the inhibition of angiogenesis |
| 02/05/2003 | EP1280774A1 Substituted indoles as parp inhibitors |
| 02/05/2003 | EP1280546A1 Method and composition for the treatment of angiogenesis |
| 02/05/2003 | EP1280537A2 Compositions of non-ionic block copolymers to treat autoimmune, proliferative, and inflammatory diseases and methods of use thereof |
| 02/05/2003 | EP1280524A2 Methods and compositions for modulating alpha adrenergic receptor activity |
| 02/05/2003 | EP1280515A2 Pharmaceutical compositions comprising cannabis |
| 02/05/2003 | EP1223918B1 Pharmaceutical compositions comprising a hmg coa reductase inhibitor |
| 02/05/2003 | EP1117653B1 Quinoline and quinazoline derivatives and their use as inhibitors of cytokine mediated diseases |